Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jul;51(7):1660-1671.
doi: 10.1002/eji.202049043. Epub 2021 May 7.

CCR4 in cutaneous T-cell lymphoma: Therapeutic targeting of a pathogenic driver

Jan P Nicolay  1   2   3 , Jana D Albrecht  1   2   3 , Silvia Alberti-Violetti  4 , Emilio Berti  4
Affiliations
Free article
Review

CCR4 in cutaneous T-cell lymphoma: Therapeutic targeting of a pathogenic driver

Jan P Nicolay et al. Eur J Immunol. 2021 Jul.
Free article

Abstract

New treatments are needed for patients with cutaneous T-cell lymphoma (CTCL), particularly for advanced mycosis fungoides (MF) and Sezary syndrome (SS). The immunopathology of MF and SS is complex, but recent advances in tumor microenvironment understanding have identified CCR4 as a promising therapeutic target. CCR4 is widely expressed on malignant T cells and Tregs in the skin and peripheral blood of patients with MF and SS. The interaction of CCR4 with its dominant ligands CCL17 and CCL22 plays a critical role in the development and progression of CTCL, facilitating the movement into, and accumulation of, CCR4-expressing T cells in the skin, and recruiting CCR4-expressing Tregs into the tumor microenvironment. Expression of CCR4 is upregulated at all stages of MF and in SS, increasing with advancing disease. Several CCR4-targeted therapies are being evaluated, including "chemotoxins" targeting CCR4 via CCL17, CCR4-directed chimeric antigen receptor-modified T-cell therapies, small-molecule CCR4 antagonists, and anti-CCR4 monoclonal antibodies. Only one is currently approved: mogamulizumab, a defucosylated, fully humanized, anti-CCR4, monoclonal antibody for the treatment of relapsed/refractory MF and SS. Clinical trial da1ta confirm that mogamulizumab is an effective and well-tolerated treatment for relapsed/refractory MF or SS, demonstrating the clinical value of targeting CCR4.

Keywords: CCR4; Sezary syndrome; cutaneous T-cell lymphoma; mogamulizumab; mycosis fungoides.

PubMed Disclaimer

References

    1. Kim, Y. H., Willemze, R., Pimpinelli, N., Whittaker, S., Olsen, E. A., Ranki, A., Dummer, R. et al., TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sézary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC). Blood 2007. 110: 479-484.
    1. Kim, E. J., Hess, S., Richardson, S. K., Newton, S., Showe, L. C., Benoit, B. M., Ubriani, R. et al., Immunopathogenesis and therapy of cutaneous T cell lymphoma. J. Clin. Invest. 2005. 115: 798-812.
    1. Krejsgaard, T., Lindahl, L. M., Mongan, N. P., Wasik, M. A., Litvinov, I. V., Iversen, L., Langhoff, E. et al., Malignant inflammation in cutaneous T-cell lymphoma: a hostile takeover. Semin. Immunopathol. 2017. 39: 269-282.
    1. Pulitzer, M. P., Horna, P. and Almeida, J., Sézary syndrome and mycosis fungoides: an overview, including the role of immunophenotyping. Cytometry B Clin. Cytom. 2021. 100: 132-138.
    1. Moins-Teisserence, H., Daubord, M., Clave, E., Douay, C., Félix, J., Marie-Cardine, A., Ram-Wolff, C. et al., CD158k is a reliable marker for diagnosis of Sézary syndrome and reveals an unprecedented heterogeneity of circulating malignant cells. J. Invest. Dermatol. 2015. 135: 247-257.

Publication types

MeSH terms

Substances